Linnea SA has been granted a narcotics license by Swissmedic making it one of the first companies in Switzerland to be able to produce and export high THC Active Pharmaceutical Ingredients (APIs).
Linnea Cannabinoids, a project of Linnea SA, is aiming to manufacture the highest-quality pharmaceutical cannabinoid ingredients and drive research and innovation within the global industry.
Linnea has stated that gaining a narcotics license will allow the company to export its standardised and innovative high-THC APIs anywhere in the world where the importation of the products is legal.
Read more: Celadon granted MHRA GMP certification for cannabis API
CEO of Linnea SA, Susanne Caspar, commented: “We are so honoured to be granted a narcotics license in Switzerland, this opens up many new commercial possibilities for Linnea Cannabinoids and our customers.
“High-quality cannabinoid ingredients are essential to producing the pharmaceutical products that patients need, and we are eager to contribute our expertise to this effort.
Read more: Flora Growth confirms direct distribution lines to Europe
“We look forward to the opportunities this will afford us in creating new partnerships and continuing to innovate in the industry.”
Linnea, which has been providing gold-standard botanical ingredients for use in the pharmaceutical, cosmetics and dietary supplement industries for over 40 years, moved into the cannabis and cannabinoid industries in 2016. The company is currently expanding its portfolio and bringing its pharmaceutical cannabinoid products to a wider global audience.
